Research conducted at the Lady Davis Institute provides proof of concept that an existing drug holds promise for reversing loss of memory and brain lesions associated with Alzheimer disease.
New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model. Importantly, this drug has already proven to be non-toxic for humans in a clinical setting and could, therefore, be brought quickly to trials in humans against AD. These findings are published today in Nature Communications.
For years, Dr. Andréa LeBlanc, Senior Investigator at the LDI and Professor of Neurology and Neurosurgery at McGill University, has strived to identify early neurodegenerative events responsible for age-related memory loss. Her team discovered that the Caspase-6 enzyme is highly activated in Alzheimer disease brain lesions and associated with loss of memory. She, therefore, pursued the hypothesis that stopping Caspase-6 might provide relief from memory loss and stop progressive dementia. Since there are no specific Caspase-6 inhibitors, the LeBlanc team moved upstream, ultimately discovering that Caspase-1 was responsible for activating Caspase-6.
“This was a significant revelation because Caspase-1 inhibitors had been developed for treating inflammatory diseases,” explains Dr. LeBlanc. “Thus, we decided to test the effects of a particular Caspase-1 inhibitor, called VX-765, against memory loss and brain pathologies in a mouse model of Alzheimer disease.”
The work, first authored by Dr. Joseph Flores, a research associate in the LeBlanc lab, showed that VX-765 has an unprecedented beneficial effect in Alzheimer mice. The drug rapidly reverses memory loss, eliminates inflammation, and stops Alzheimer’s prototypical amyloid peptide accumulation in the mice brains. In addition to being safe for humans at relatively high doses for extended periods of time, it is capable of reaching the brain, a significant challenge in the development of drugs against disorders of the brain.
While Dr. LeBlanc cautions that there is a considerable bridge to cross between the mouse brain and that of a human, she believes that since her work has first identified the Caspase-1/Caspase-6 neurodegenerative pathway in human neurons and in human Alzheimer brains, there is a chance that this drug will work just as well in humans as it did in mice. Nevertheless, a clinical trial is needed to determine whether the drug will be beneficial against Alzheimer disease in humans.
Presently, there are no efficient treatments to significantly treat Alzheimer disease, the major affliction in a group of dementias that affect 47.5 million individuals worldwide.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Warning Signs of Alzheimers Diseaseon November 14, 2019 at 8:40 am
Another example might be making occasional mistakes while paying bills or cooking. Some of the warning signs of Alzheimers Disease are: It may be disturbing to see a loved one exhibit these warning ...
- Todos and Amarantus JV Announces Full Enrollment forClinical Trial of LymPro Alzheimers Blood Test Relationship with Amyloid PETon November 14, 2019 at 7:02 am
REHOVOT, Israel and NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) — Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early ...
- Alzheimers Disease Diagnostic Market Growth, Latest Trend and Forecast 2019-2026on November 12, 2019 at 11:37 pm
Nov 13, 2019 (Global QYResearch via COMTEX) -- The report on Global Alzheimers Disease Diagnostic Market is the latest addition to the huge database of Ameco Research. This research study is segmented ...
- November is Alzheimers Awareness Monthon November 11, 2019 at 9:00 am
CLIFTON — November is recognized as Alzheimer’s Awareness Month, a disease with a staggering cost to Americans. In 1983, President Ronald Reagan designated November as National Alzheimer’s Awareness ...
- Care for the Alzheimers caregiver: In North Iowa, you are not aloneon November 10, 2019 at 10:18 am
After age 65, risk of Alzheimers doubles every five years • At least 32% of Americans age 80 and older have Alzheimers • An estimated 15 million unpaid caregivers provide 18.2 billion hours of service ...
- WATCH Dolls, stuffed animals bring connection to Kentucky Alzheimers patientson November 8, 2019 at 4:14 pm
Taking care of baby dolls and stuffed animals may seem like childs play, but for seniors with Alzheimer's and dementia, it's a proven form of therapy.
- Hundreds nearly reach fundraising goal after walk for Alzheimers researchon November 8, 2019 at 2:36 am
More than 800 residents attended the walk over the weekend, raising more than $97,000 to support the Alzheimers Associations several research programs. More than 800 residents attended the walk over ...
- Facing Alzheimer'son November 7, 2019 at 9:09 pm
He competed in long distance bike races and half marathons all over the country. "The bigger the hardware you got when you finished, those were the runs that he ran in," said Kathy While these ...
- Alzheimer’s Drugs Market Size, Global Trends, Top Key Players and Industry Growth by Forecast till 2026on November 7, 2019 at 8:50 pm
Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/alzheimers-drugs-market-101033 List of key companies mentioned in Alzheimer's Disease Drug Market report, The ...
via Bing News